Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental combo aims to tackle tough lymphomas

NCT ID NCT05272384

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether combining the immunotherapy drug nivolumab with the drug ASTX727 can help shrink or stabilize B-cell lymphomas that have returned or are not responding to treatment. About 32 adults with certain types of lymphoma will receive the combination to find the safest dose and check for side effects. The goal is to see if this approach can offer a new option for patients who have run out of standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nivolumab and ASTX727 (decitabine and cedazuridine)
What this could lead to
If it works, this could point toward a new treatment option for people with lymphoma that has come back or stopped responding to other therapies.
What could go wrong
This is a very early phase 1 trial with only 32 participants, so it is primarily testing safety and dosing. The combination may not work well or could cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma diffuse large B-cell lymphoma Hodgkins lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT B-CELL NON-HODGKIN LYMPHOMA RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT HODGKIN LYMPHOMA REFRACTORY B-CELL NON-HODGKIN LYMPHOMA REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY HODGKIN LYMPHOMA

Contacts and locations

Locations

  • City of Hope Comprehensive Cancer Center

    RECRUITING

    Duarte, California, 91010, United States

    Contact Email: •••••@•••••

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone

    RECRUITING

    New York, New York, 10016, United States

    Contact Email: •••••@•••••

  • NYU Langone Hospital - Long Island

    RECRUITING

    Mineola, New York, 11501, United States

    Contact Email: •••••@•••••

  • UC Comprehensive Cancer Center at Silver Cross

    RECRUITING

    New Lenox, Illinois, 60451, United States

    Contact Email: •••••@•••••

  • University of Alabama at Birmingham Cancer Center

    ACTIVE_NOT_RECRUITING

    Birmingham, Alabama, 35233, United States

  • University of California Davis Comprehensive Cancer Center

    RECRUITING

    Sacramento, California, 95817, United States

  • University of Chicago Comprehensive Cancer Center

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact Email: •••••@•••••

  • University of Chicago Medicine-Orland Park

    RECRUITING

    Orland Park, Illinois, 60462, United States

    Contact Email: •••••@•••••

  • Yale University

    RECRUITING

    New Haven, Connecticut, 06520, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.